Diagnostic testing of CSF for surrogate disease markers (i.e., 14-3-3 and total tau) assumes that the patient had a history of acute dementia but did not have several conditions that might compromise ...
Novel cerebrospinal fluid (CSF) biomarkers can potentially identify patients with one or other of the two main forms of frontotemporal lobar degeneration (FTLD), according to research conducted by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback